WGSWW — GeneDx Holdings Corp.

Summary of GeneDx Holdings Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $102.3 million, with exome and genome revenue at $90.6 million (up 27% year-over-year).
• Test Volume: 27,488 tests, reflecting a 34% increase year-over-year.
• Blended Average Reimbursement Rate (ARR): Approximately $3,300, impacted by product mix.
• Adjusted Gross Margin: 69%.
• Adjusted Net Loss: $8.2 million.
• Impairment Charge: $31.3 million related to goodwill and intangible assets.

2. Strategic Updates and Business Highlights

• GeneDx is transitioning from multi-gene panels to comprehensive exome and genome testing, with a strong focus on expanding its market share.
• The company identified opportunities to improve reimbursement dynamics and has taken actions to enhance commercial execution and revenue cycle management.
• The Fabric Genomics acquisition is being integrated into GeneDx, with a focus on international growth and a recalibration of revenue expectations for 2026.
• The company launched a Reflex offering to balance clinical demand and improve gross margins.

3. Forward Guidance and Outlook

• Updated Revenue Guidance: Total revenues expected to be between $475 million and $490 million for 2026, down from previous estimates.
• Volume Growth: Anticipated growth of at least 30% in exome and genome testing, translating to approximately 126,400 tests.
• Adjusted Gross Margin: Expected to remain around 70%.
• Q2 2026 Guidance: Projected revenues of $110 million to $112 million, with an adjusted net loss of approximately $5 million.

4. Bad News, Challenges, or Points of Concern

• Revenue fell short of expectations by $12 million due to a lower-than-expected blended ARR and underperformance in non-core business lines.
• The company is facing challenges with reimbursement rates for genome testing, which are currently lower than exome rates and impacted by denial rates.
• The integration of the expanded sales force has led to execution challenges, particularly in activating accounts in new markets.
• A non-cash impairment charge reflects difficulties in the Fabric business and slower-than-anticipated sales cycles in the biopharma segment.

5. Notable Q&A Insights

• Management acknowledged the need for better visibility and forecasting precision, particularly regarding product mix shifts that affected Q1 results.
• The company is focused on optimizing unit economics and improving reimbursement rates for genome testing, with expectations for rates to strengthen over time.
• There is confidence in the core business's ability to drive profitable growth, with a commitment to return to adjusted profitability by the end of 2026.
• The sales force's productivity is still in early stages, and adjustments are being made to improve performance across different segments.
• Competitive dynamics remain stable, with no significant new entrants affecting the market, although there is ongoing development in long-read sequencing capabilities.

Overall, while GeneDx Holdings Corp. demonstrated strong volume growth and strategic initiatives, it faces challenges in revenue realization and reimbursement dynamics that have led to a cautious outlook for the remainder of 2026.